FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
The US Federal Trade Commission has ordered Aurobindo Pharma to divest four generic drugs to complete its $250 million acquisition of Lannett Company Inc.
- Country:
- United States
The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.
Google News